| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/25/2011 | US7875265 A cosmetic composition comprising a specific block polymer and a specific plasticizer intended to be applied to human keratinous substances, such as the skin, lips, eyelashes, eyebrows, nails or hair; film-forming acrylic polymers containing a plasticizer; flexibility; good hold; transfer-free |
| 01/25/2011 | US7875261 Staining; for detecting reactive oxygen species such as hydrogen peroxide; used in immunology, diagnostics, molecular biology and fluorescence based assays |
| 01/25/2011 | CA2642851C Low flush niacin formulation |
| 01/25/2011 | CA2635963C Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof |
| 01/25/2011 | CA2628200C Solid pharmaceutical compositions containing pregabalin |
| 01/25/2011 | CA2601025C Novel derivatives of phosphinic amino acids, preparation method thereof and pharmaceutical compositions containing same |
| 01/25/2011 | CA2599158C Pharmaceutical agent comprising solifenacin |
| 01/25/2011 | CA2576297C Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors |
| 01/25/2011 | CA2540247C Prodrugs of amino acids with affinity for the .alpha.2.delta.-protein |
| 01/25/2011 | CA2539760C Quinoline potassium channel inhibitors |
| 01/25/2011 | CA2535370C Isothiazoloquinolones and related compounds as anti-infective agents |
| 01/25/2011 | CA2506648C 4-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors |
| 01/25/2011 | CA2496540C Stable ophthalmic solution comprising latanoprost as active ingredient |
| 01/25/2011 | CA2494323C Amino benzothiazole compounds with nos inhibitory activity |
| 01/25/2011 | CA2491836C 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder |
| 01/25/2011 | CA2490141C 1-[(indol-3-yl)carbonyl]piperazine derivatives |
| 01/25/2011 | CA2483448C Anti-acne compositions and methods of use |
| 01/25/2011 | CA2483090C Use of therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions |
| 01/25/2011 | CA2480367C 4-(diarylmethyl)-1-piperazinyl derivatives |
| 01/25/2011 | CA2477714C New cinnamic acid salts, processes for the preparation thereof and use thereof as medicament |
| 01/25/2011 | CA2476983C Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma |
| 01/25/2011 | CA2472776C Process for the manufacture of hmg-coa reductase inhibitors |
| 01/25/2011 | CA2469594C Crystal of bicalutamide and production method thereof |
| 01/25/2011 | CA2468681C Adenosine a2a receptor antagonists |
| 01/25/2011 | CA2468673C Compounds specific to adenosine a1 and a3 receptors and uses thereof |
| 01/25/2011 | CA2468180C Anti-proliferative composition |
| 01/25/2011 | CA2463146C Crystalline sodium salt of telmisartan and the use of same as an angiotensin antagonist |
| 01/25/2011 | CA2458690C Pharmaceutical compositions comprising an ascomycin derivative |
| 01/25/2011 | CA2458528C C2-substituted indan-1-ones and their derivatives, processes for their preparation and their use as medicaments |
| 01/25/2011 | CA2457856C Sulphonated meso-tetraphenyl chlorins and their use as therapeutic agents |
| 01/25/2011 | CA2454532C Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities |
| 01/25/2011 | CA2450962C Drug delivery devices |
| 01/25/2011 | CA2449066C Nicotine-containing film preparation |
| 01/25/2011 | CA2447765C 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| 01/25/2011 | CA2443868C 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders |
| 01/25/2011 | CA2441834C Lipid profile modulation |
| 01/25/2011 | CA2434299C Tricyclic androgen receptor modulator compounds and methods |
| 01/25/2011 | CA2433414C Process for the isolation and purification of epothilones |
| 01/25/2011 | CA2432582C Sulfamidothienopyrimidines |
| 01/25/2011 | CA2430857C Percutaneous absorption-type pharmaceutical preparation and process for producing the same |
| 01/25/2011 | CA2430182C Prokaryotically produced antibodies and uses thereof |
| 01/25/2011 | CA2413928C Corneal epithelial migration promoter |
| 01/25/2011 | CA2410233C Compounds for treating impaired fundic relaxation |
| 01/25/2011 | CA2404125C Sulphonamido-substituted bridged bicycloalkyl derivatives |
| 01/25/2011 | CA2391650C Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl |
| 01/25/2011 | CA2388468C Mediators of hedgehog signalling pathways, compositions and uses related thereto |
| 01/25/2011 | CA2384425C Methods and compositions for delivery of pharmaceutical agents |
| 01/25/2011 | CA2381882C Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 01/25/2011 | CA2369826C Therapy of cardiac insufficiency |
| 01/25/2011 | CA2368849C Process for preparing amine platinum complexes |
| 01/25/2011 | CA2363053C Clopidogrel bisulfate tablet formulation |
| 01/25/2011 | CA2355768C Injectable hyaluronic acid derivative with pharmaceuticals/cells |
| 01/25/2011 | CA2339834C Water soluble prodrugs of hindered alcohols or phenols |
| 01/25/2011 | CA2338186C Tumor necrosis factor-gamma |
| 01/25/2011 | CA2337857C Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate |
| 01/25/2011 | CA2334200C Pyrrolo[2,3d]pyrimidine compositions and their use |
| 01/25/2011 | CA2317455C Hydroxamic and carboxylic acid derivatives |
| 01/25/2011 | CA2303509C Modified timp |
| 01/25/2011 | CA2292378C A method of inhibiting cancer cell growth using a vector expressing prb2/p130 |
| 01/25/2011 | CA2281858C A method for making infectious, propagation defective tr339 virus particles and helper cells therefor |
| 01/25/2011 | CA2200603C Emulsifiable composition for the control of insects |
| 01/25/2011 | CA2175429C Pharmaceutical compositions and methods |
| 01/25/2011 | CA2174098C Method of inducing and maintaining neuronal cells |
| 01/25/2011 | CA2163278C Method for production of arachidonic acid |
| 01/21/2011 | CA2709551A1 New piperidine compounds, their preparation process and the pharmaceutical compositions containing these compounds |
| 01/21/2011 | CA2709341A1 New chromene derivatives, their preparation process and the pharmaceutical compositions containing these derivatives |
| 01/20/2011 | WO2011009119A2 Compositions and methods for diagnosing and treating fibrotic disorders |
| 01/20/2011 | WO2011009115A2 Combination therapies for the treatment of obesity |
| 01/20/2011 | WO2011009102A1 Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia |
| 01/20/2011 | WO2011009097A2 Methods for treating schizophrenia |
| 01/20/2011 | WO2011009095A1 Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quin0lin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
| 01/20/2011 | WO2011009084A2 Benzimidazole analogues for the treatment or prevention of flavivirus infections |
| 01/20/2011 | WO2011009075A2 Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| 01/20/2011 | WO2011009061A1 Compositions comprising a cholinesterase inhibitor for treating cognitive disorders |
| 01/20/2011 | WO2011009059A2 Method of treating or preventing cancer |
| 01/20/2011 | WO2011009047A2 Il-1ra-polymer conjugates |
| 01/20/2011 | WO2011009039A2 Pharmaceutical for oral delivery comprising mgbg and methods of treating disease |
| 01/20/2011 | WO2011009023A1 Tazarotene derivatives |
| 01/20/2011 | WO2011009020A2 Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
| 01/20/2011 | WO2011009016A1 Treatment method |
| 01/20/2011 | WO2011009015A1 (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| 01/20/2011 | WO2011009012A1 METHODS OF SUPPRESSING APPETITE BY THE ADMINISTRATION OF ANTAGONISTS OF THE SEROTONIN HTR1a or HTR2b RECEPTORS OR INHIBITORS OF TPH2 |
| 01/20/2011 | WO2011009010A1 Novel compounds for inhibiting eef2 kinase activity |
| 01/20/2011 | WO2011008976A1 N-acetyl cysteine compositions and methods to improved the therapeutic efficacy of acetaminophen |
| 01/20/2011 | WO2011008956A2 Mammalian genes involved in infection |
| 01/20/2011 | WO2011008947A2 Treatment and diagnosis of immune disorders |
| 01/20/2011 | WO2011008931A2 Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| 01/20/2011 | WO2011008915A1 Pyrrolopyridine inhibitors of kinases |
| 01/20/2011 | WO2011008868A1 Thin film compositions and methods of synthesis and use therefor |
| 01/20/2011 | WO2011008823A2 Peptide-mediated non-covalent delivery of active agents across the blood brain barrier |
| 01/20/2011 | WO2011008809A1 Crystalline freebase forms of a biphenyl compound |
| 01/20/2011 | WO2011008800A1 Pet food compositions including a sustained-release lipoic acid and methods of manufacture and use thereof |
| 01/20/2011 | WO2011008788A1 Fluoro-substituted compounds as kinase inhibitors and methods of use thereof |
| 01/20/2011 | WO2011008730A2 Chemical modification of small hairpin rnas for inhibition of gene expression |
| 01/20/2011 | WO2011008709A1 Apoptosis signal-regulating kinase inhibitors |
| 01/20/2011 | WO2011008686A1 Exo-s-mecamylamine method, use, and compound for treatment |
| 01/20/2011 | WO2011008675A2 Catecholamine compounds, compositions, and formulations, and methods of using the same |
| 01/20/2011 | WO2011008674A1 Material and process for incorporation of low dosage active pharmaceutical ingredients and use thereof |
| 01/20/2011 | WO2011008663A1 Gpr119 agonists |
| 01/20/2011 | WO2011008640A1 Methods of increasing liver proliferation |